Bibliography
- Matsubara K , FukayaT: The role of superantigens of group A streptococcus and staphylococcus aureus in Kawasaki disease.Curr. Opin. Infect. Dis.20(3), 298–303(2007).
- Shulman ST , TanzRR: Streptococcus pyogenes (group A streptococcus). In: Principles and Practice of Pediatric Infectious Diseases. Long SS, Pickering LK, Prober CG (Ed.), Churchill Livingstone, Philadelphia, PA, USA 716–719(2003).
- Pruksakorn S , CurrieB, BrandtEet al.: Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci.Int. Immunol.6, 1235–1244(1994).
- Factor SH , LevineOS, HarrisonLHet al.: Risk factors for pediatric invasive group A streptococcal disease.Emerg. Infect. Dis.11(7), 1062–1066(2005).
- Factor SH , LevineOS, SchwartzBet al.: Invasive group A streptococcal disease: risk factor for adults.Emerg. Infect. Dis.9, 970–977(2003).
- Robinson K , RothrockG, PhanQet al.: risk for severe group A streptococcal disease among patients’ household contacts.Emerg. Infect. Dis.9, 443–447(2003).
- American Academy of Pediatrics Committee on Infectious Diseases: Severe invasive group A streptococcal infections: a subject review. Pediatrics.101, 136–140(1998).
- The Prevention of invasive group a streptococcal infections workshop participants: prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the centers for disease control and prevention. Clin. Infect. Dis.35, 950–959(2002).
- Public Health Agency of Canada: guidelines for the prevention and control of invasive group A streptococcal disease. CCDR32S2, 1–26(2006).
- O‘Brien KL , BeallB, BarrettNLet al.: Epidemiology of invasive group A streptococcus disease in the United States, 1995–1999.Clin. Infect. Dis.35(3), 268–276(2002).
- Forni AL , KaplanEL, SchlievertPM, RobertsRB: Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome.Clin. Infect. Dis.21, 333–340(1995).
- Hoge CW , SchwartzB, TalkingtonDF, BreimanRF, NacNeillEM, EnglenderSJ: The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome.JAMA269(3), 384–389(1993).
- The working group on severe streptococcal infections: defining the group A streptococcal toxic shock syndrome. rational and consensus definition. JAMA269(3), 390–391(1993).
- Patel RA , BinnsHJ, ShulmanST: Reduction in pediatric hospitalizations for varicella related invasive group A streptococcal infections in the varicella vaccine era.J. Pediatr.144(1), 68–74(2004).
- Conley J , OlsonME, CookLS, CeriH, PhanV, DaviesHD: Biofilm formation by group A streptococci: is there a relationship with treatment failure?J. Clin. Microbiol.41, 4043–4048(2003).
- Stevens DL , YanS, BryantAE: Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect.J. Infect. Dis.167(6), 1401–1405(1993).
- Zimbelman J , PalmerA, ToddJ: Improved outcome of clindamycin compared with β-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.Pediatr. Infect. Dis. J.18(12), 1096–1100(1999).
- Mehta S , McGeerA, LowDEet al.: morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU.Chest130, 1679–1686(2006).
- Martin JM , GreenM, BarbadoraKA, Wald ER: Group A streptococci among school-aged children: clinical characteristics and the carrier state. Pediatrics114(5), 1212–1219(2004).
- Richter SS , HeilmannKP, BeekmannSEet al.: Macrolide-resistant Streptococcus pyogenesin the United States, 2002–2003. Clin. Infect. Dis.41(5), 599–608(2005).
- Kaul R , McGreerA, Norrby-TeglundAet al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome – a comparative observational study. Clin. Infect. Dis.28, 800–807(1999).
- Norrby-Teglund A , MullerM, McGeerAet al.: Successful management of severe group a streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand. J. Infect. Dis.37, 166–172(2005).
- Stevens DL , TannerMH, WinshipJet al.: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.N. Engl. J. Med.321(1), 1–7(1989).
- Wilson B : Necrotizing fasciitis.Am. Surg.18, 416 (1952).
- Anaya DA , DellingerEP: Necrotizing soft-tissue infection: diagnosis and management.Clin. Infect. Dis.44, 705–710(2007).
- Stevens DL , BisnoAL, ChambersHFet al.: Infectious disease society of america practice guidelines for the diagnosis and management of skin and soft-tissue infections.Clin. Infect. Dis.41, 1373–1406(2005).
- Stevens DL : Streptococcal toxic-shock syndrome associated with necrotizing fasciitis.Annu. Rev. Med.51, 271–288(2000).
- Stevens DL : Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment.Emerg. Infect. Dis.1, 69–78(1995).
- Wong CH , KhinLW, HengKS, TanKC, LowCO: The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections.Crit. Care Med.32, 1535–1541(2004).
- Wysoki MG , SantoraTA, ShahRM, FriedmanAC: Necrotizing fasciitis: CT characteristics.Radiology203, 859–863(1997).
- Norrby-Teglund A , KaulR, LowDEet al.: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T-cell proliferation and cytokine production.J. Immunol.156(8), 3057–3064(1996).
- Davies HD , McGeerA, SchwartzBet al.: invasive group a streptococcal infections in Ontario, Canada.NEJM335, 547–554(1996).
- Campbell JR , ArangoCA, Garcia-PratsJA, BakerCJ: An outbreak of M serotype 1 group A streptococcus in a neonatal intensive care unit.J. Pediatr.129(3), 396–402(1996).
- O‘Brien KL , BeallB, BarrettNLet al.: epidemiology of invasive group a streptococcus disease in the United States, 1995–1999.Clin. Infect. Dis.35, 268–276(2002).
- Stevens DL : Invasive Group A streptococcus infections.Clin. Infect. Dis.14(1), 2–11(1992).
- Doctor A , HarperMB, FleisherGR: Group A beta-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella.Pediatrics.96, 428–433(1995).
- Dale JB , PenfoundT, ChiangEY, LongV, ShulmanST, BeallB: Multivalent group A streptococcal vaccine elicits bactericidal Antibodies against variant M subtypes.Clin. Diagn. Lab. Immunol.12(7), 833–836(2005).
- McNeil SA , HalperinSA, LangleyJM: Safety and immunogenicity of 25-valent group a streptococcus vaccine in healthy adult volunteers.Clin. Infect. Dis.41, 1114–1122(2005).
- Olive C , HoMF, DyerJet al.: immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.J. Infect. Dis.193, 1666–1676(2006).
- Brandt ER , HaymanWA, CurrieB, PruksakornS, GoodMF: Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci.Vaccine15, 1805–1812(1997).
- Olive C , SunHK, HoMFet al.: Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.J. Infect. Dis.194, 316–24(2006).